Drug Type Bispecific T-cell Engager (BiTE), Probody |
Synonyms TROP2TRACTr, Trophoblast Antigen 2 Tumour Activated TCell Engager therapy |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | US | 01 Nov 2022 | |
Transitional Cell Carcinoma | Preclinical | US | 01 Nov 2022 | |
Triple Negative Breast Cancer | Preclinical | US | 01 Nov 2022 |